https://medicalxpress.com/news/2024-03-fda-car-cell-therapy-adults.html
Another CAR-T approval. First therapy for adults with leukemia or lymphoma, another bar set.
Accelerated approval was based on response rate and duration of response.
"The results of the phase 1/2 trial of 89 patients indicated a complete response rate of 20 percent with Breyanzi treatment"
"The overall response rate was 45 percent, with a median duration of response of 35.3 months. Across patients treated with Breyanzi who achieved a complete response, the minimal residual disease negativity rate was 100 percent in the blood and 92.3 percent in the bone marrow"
- Forums
- ASX - By Stock
- Ann: Clinical milestones for 2024 & 2023 successes highlighted
https://medicalxpress.com/news/2024-03-fda-car-cell-therapy-adult...
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.8¢ |
Change
0.001(3.70%) |
Mkt cap ! $23.97M |
Open | High | Low | Value | Volume |
2.7¢ | 2.8¢ | 2.7¢ | $1.457K | 52.88K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 1378547 | 2.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.8¢ | 140734 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 1378547 | 0.027 |
7 | 779615 | 0.026 |
6 | 910000 | 0.025 |
11 | 1586666 | 0.024 |
8 | 2330300 | 0.023 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 140734 | 2 |
0.029 | 342970 | 2 |
0.030 | 216203 | 2 |
0.031 | 451071 | 4 |
0.032 | 1550000 | 3 |
Last trade - 10.43am 07/05/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online